Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06408493
Other study ID # 36440
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2024
Est. completion date December 2024

Study information

Verified date March 2024
Source Monash University Malaysia
Contact Lim Geok Pei, MSc
Phone +60163938743
Email geok.lim@monash.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this interventional study is to develop and assess the effectiveness of a peer-led digital health program (MYCardio-PEER) for primary prevention of cardiovascular disease (CVD) in a low-income community at-risk of CVD. The main questions it aims to answer are: - Is MYCardio-PEER effective in improving knowledge, lifestyle behaviors and CVD biomarkers of a low-income community at-risk for CVD? - Is there an association between MYCardio-PEER participants' adherence and satisfaction, with effectiveness and sustainability of the program? Participants will attend the 8-weeks MYCardio-PEER program with their peer leaders, supplemented with face-to-face components. Participants will then be followed up for another 12 weeks, during which peer leaders and researchers will have minimal contact with the participants. Participants who have been allocated into the control group will receive printed documents with standard tips on dietary and lifestyle management for CVD, where they will be encouraged to maintain regular calorie intake and expenditure and perform regular exercise.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date December 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 30 Years to 74 Years
Eligibility Inclusion Criteria: - Mentally sound man/woman of at least 30 years old - Monthly household income of less than RM3,710 or receiving government aid for low-income community - Literate with a fair command of the Malay language - Have mobile device connected to the Internet - Willing to attend 8 weeks of intervention and be followed up for another 12 weeks during the maintenance phase. - Have been confirmed to have a moderate or high risk for CVD based on the Framingham General CVD Risk Score Exclusion Criteria: - Pregnant, lactating or intend to become pregnant during the study period. - Any other pre-existing conditions or severe complications that could compromise the ability to adhere to the study program. - Enrolled in other studies.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
MYCardio-PEER
MYCardio-PEER participants will attend an 8-weeks intervention program delivered over the social networking application. Bite-sized videos and infographic posters on healthy diet and lifestyle for primary prevention of CVD will be delivered weekly, supplemented by interactive peer-group activities to encourage behavior change.

Locations

Country Name City State
Malaysia Monash University Subang Jaya Selangor

Sponsors (2)

Lead Sponsor Collaborator
Monash University Malaysia Ministry of Higher Education, Malaysia

Country where clinical trial is conducted

Malaysia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Framingham Risk Score for Cardiovascular Disease Risk The score is based on a person's age, sex, blood pressure, cholesterol levels, smoking status, and diabetes status. The calculated score will be converted into 10-year risk percentage whereby the higher the percentage means higher cardiovascular disease risk. 20 weeks
Secondary Blood pressure The blood pressure will be measured in mmHg. Blood pressure more than 140/90 mmHg is considered high blood pressure. 20 weeks
Secondary Total cholesterol level Total cholesterol will be measured in mmol/L. Total cholesterol more than 5.2 mmol/L is considered high. 20 weeks
Secondary High-density lipoprotein cholesterol (HDL-C) level High-density lipoprotein cholesterol (HDL-C) will be measured in mmol/L. The healthy cut-off points of HDL-C in male is more than 1.0 mmol/L and in female more than 1.3 mmol/L. 20 weeks
Secondary Low-density lipoprotein cholesterol (LDL-C) level Low-density lipoprotein cholesterol (LDL-C) will be measured in mmol/L. The healthy cut-off point of LDL-C is less than 2.6 mmol/L. 20 weeks
Secondary Triglycerides level Triglycerides level will be measured in mmol/L. The healthy cut-off point of triglycerides level is less than 1.7 mmol/L. 20 weeks
Secondary Fasting blood glucose level Fasting blood glucose level will be measured in mmol/L. The healthy cut-off point of fasting blood glucose level is less than 6.1 mmol/L. 20 weeks
Secondary Body weight Body weight will be assessed in kilograms. 20 weeks
Secondary Body height Body height will be assessed in meters. Baseline
Secondary Body mass index Body mass index (BMI) is derived from body weight in kilograms (kg) and body height in meters (m). BMI is expressed as kg/m^2. 20 weeks
Secondary Waist circumference Waist circumference will be assessed in centimeters (cm). The healthy cut-off point of waist circumference for male is less than or equal to 90cm and for female less than or equal to 80cm. 20 weeks
Secondary Attitude and Beliefs about Cardiovascular Risk Attitude and Beliefs about Cardiovascular Risk will be assessed using the Attitude and Beliefs about Cardiovascular Risk - Malay questionnaire. The overall score was calculated from all item scores by the domains. The higher the score, the higher the awareness and the readiness to change the behavior. 20 weeks
Secondary Physical activity level The physical activity level will be assessed using the International Physical Activity Questionnaire. The intensity of self-reported physical activity lasting at least 10 minutes per bout was measured in metabolic equivalent (MET). The accumulated MET-minutes per week will be calculated to categorize into low, moderate (at least 600 MET-minutes per week) or high physical activity level (at least 3000 MET-minutes per week). 20 weeks
Secondary Medication Understanding and Taking Self-Efficacy The Medication Understanding and Taking Self-Efficacy will be assessed using the Medication Understanding and Taking Self-Efficacy scale. The scores ranged from 8 to 32, with higher scores indicating greater levels of medication understanding. 20 weeks
Secondary Dietary intakes The usual dietary intakes will be assessed using the short food frequency questionnaire. It provides details on daily intake of food groups. 20 weeks
Secondary Nutrient intakes Nutrient intakes will be assessed using the 2-day 24-hour diet recalls. The participants will be asked about all details of the foods and beverages consumed in the past 24 hours, including the types of food, cooking methods, estimated portion size and brands. Nutrient intakes from 24-hour dietary recalls will be analyzed with Nutritionist Pro software (Axxya Systems, USA) to yield total energy, macronutrient and micronutrient intakes. 20 weeks
Secondary Stress level The stress level will be assessed using the Perceived Stress Scale (PSS). Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.
0-13 = low stress
14-26 = moderate stress
27-40 = high perceived stress
20 weeks
Secondary Smoking habit Participants will be asked if they are non-smoker, past smoker or current smoker; how long have you been smoking; and how many cigarettes did/do you smoke per day? 20 weeks
Secondary Alcohol consumption Participants will be asked if they are non-drinker, past drinker or current drinker; how long (years) have you been consuming alcohol? 20 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03387384 - Appropriateness of Aspirin Use in Medical Outpatients